0.309
Precedente Chiudi:
$0.319
Aprire:
$0.3161
Volume 24 ore:
34,684
Relative Volume:
0.33
Capitalizzazione di mercato:
$12.86M
Reddito:
-
Utile/perdita netta:
$-74.56M
Rapporto P/E:
-0.1687
EPS:
-1.8316
Flusso di cassa netto:
$-60.27M
1 W Prestazione:
-6.16%
1M Prestazione:
+1.61%
6M Prestazione:
-73.59%
1 anno Prestazione:
-80.57%
Rallybio Corp Stock (RLYB) Company Profile
Nome
Rallybio Corp
Settore
Industria
Telefono
203- 859-3820
Indirizzo
234 CHURCH STREET, NEW HAVEN
Confronta RLYB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RLYB
Rallybio Corp
|
0.309 | 13.70M | 0 | -74.56M | -60.27M | -1.8316 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
2024-05-15 | Downgrade | JP Morgan | Overweight → Neutral |
2024-02-07 | Downgrade | Jefferies | Buy → Hold |
2023-04-17 | Iniziato | H.C. Wainwright | Buy |
2023-04-10 | Iniziato | Wedbush | Outperform |
2022-12-09 | Iniziato | JP Morgan | Overweight |
2022-02-22 | Iniziato | JMP Securities | Mkt Outperform |
2021-08-23 | Iniziato | Cowen | Outperform |
2021-08-23 | Iniziato | Evercore ISI | Outperform |
2021-08-23 | Iniziato | Jefferies | Buy |
Mostra tutto
Rallybio Corp Borsa (RLYB) Ultime notizie
Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - Trumbull Times
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook By Investing.com - Investing.com Canada
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook - Investing.com
Rallybio shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Rallybio shareholders elect directors, ratify auditor - Investing.com
Rallybio Elects New Directors at Shareholder Meeting - TipRanks
Rallybio Reports Q1 2025 Financial Results and Strategic Updates - MSN
New Haven biotech firm to cut 40% of workforce in latest round of layoffs, pivots on drug program - Stamford Advocate
Rallybio Downsizes by 40% After Dropping Lead Asset - BioSpace
Layoffs hit biotech: Vor Bio slashes 95% of staff, more cuts from insitro, Korro, Rallybio - FirstWord Pharma
4 more biotechs cut staff amid market tumult - BioPharma Dive
Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Another CT biotech company making significant workforce cuts - Hartford Business Journal
RallyBio cuts deeper, laying off 40% of workforce after halting work on lead drug - Fierce Biotech
Rallybio Corp SEC 10-Q Report - TradingView
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - Bluefield Daily Telegraph
Rallybio (RLYB) to Release Quarterly Earnings on Thursday - Defense World
Renaissance Technologies LLC Has $424,000 Stock Position in Rallybio Co. (NASDAQ:RLYB) - Defense World
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - BioSpace
Rallybio Makes Nasdaq Debut - RTTNews
Citizens JMP maintains Rallybio stock at Market Perform By Investing.com - Investing.com Nigeria
Citizens JMP maintains Rallybio stock at Market Perform - Investing.com
Rallybio (NASDAQ:RLYB) Cut to Hold at Evercore ISI - Defense World
Rallybio drops drug for rare maternal disorder following Phase II fail - MSN
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Evercore ISI Downgrades Rallybio to In Line From Outperform - marketscreener.com
Analysts Set Rallybio Co. (NASDAQ:RLYB) Price Target at $9.75 - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns - Investing.com Australia
HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB) - Defense World
Rallybio’s (RLYB) Neutral Rating Reiterated at HC Wainwright - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns By Investing.com - Investing.com India
Rallybio (NASDAQ:RLYB) Cut to Hold at Citizens Jmp - Defense World
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Rallybio to Neutral From Buy - MarketScreener
Rallybio sinks as it drops RLYB212 for prevention of FNAIT - The Pharma Letter
Rallybio ends RLYB212 program after trial setback - Investing.com Australia
Citizens JMP cuts Rallybio stock rating following program halt By Investing.com - Investing.com Canada
Rallybio stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Citizens JMP cuts Rallybio stock rating following program halt - Investing.com Australia
Rallybio Corp Azioni (RLYB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):